Article Text

Download PDFPDF
Bupropion in the treatment of postural orthostatic tachycardia syndrome (POTS): a single-center experience
  1. Rohit Vyas1,
  2. Zeid Nesheiwat1,
  3. Mohammed Ruzieh2,
  4. Zaid Ammari1,
  5. Mohammad Al-Sarie1,
  6. Blair Grubb3
  1. 1 Department of Internal Medicine, The University of Toledo Medical Center, Toledo, Ohio, USA
  2. 2 Heart and Vascular Institute, Pennsylvania State University, University Park, Pennsylvania, USA
  3. 3 Department of Cardiovascular Medicine, The University of Toledo Medical Center, Toledo, Ohio, USA
  1. Correspondence to Dr Zeid Nesheiwat, The University of Toledo Medical Center, Toledo, OH 43606, USA; nesheiwatzeid{at}gmail.com

Abstract

Postural orthostatic tachycardia syndrome (POTS) is estimated to impact millions of people each year. However, there is no established gold standard for its treatment. Bupropion is a norepinephrine and a dopamine reuptake inhibitor and has been implicated as a potential treatment for POTS. We performed a non-randomized retrospective chart review on 47 patients with POTS with statistical analysis evaluating for significant findings including reduced orthostasis and improvement of symptoms with the use of bupropion. Bupropion was not associated with a statistically significant improvement in orthostatic vitals but there was an overall reduction in reported syncope. While the use of bupropion does not show a statistically significant impact on orthostatic vitals in patients with POTS, it did show a degree of improvement in syncope and as such might be useful in patients with syncope-predominant POTS.

  • cardiology
  • cardiovascular diseases
  • cardiovascular agents
  • autonomic nervous system
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors RV, MR, and ZN assisted in the conceptualization, data curation, analysis, investigation, methodology, writing, revision, and editing. MAS and ZA assisted in the conceptualization and methodology. BG assisted in the data curation, analysis, investigation, methodology, writing, revision, editing, and supervision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Our study received institutional review board approval at The University of Toledo.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data have been deidentified. Reuse is only permitted if credited.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.